Media coverage about Amphastar Pharmaceuticals (NASDAQ:AMPH) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.7144777777359 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of NASDAQ AMPH traded down $0.10 during trading on Friday, hitting $18.02. The company had a trading volume of 93,988 shares, compared to its average volume of 140,584. The stock has a market capitalization of $849.73 million, a P/E ratio of 47.42, a P/E/G ratio of 8.37 and a beta of 1.40. Amphastar Pharmaceuticals has a 52 week low of $14.40 and a 52 week high of $20.45. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.24 and a current ratio of 1.94.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, August 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.05). The company had revenue of $71.00 million during the quarter, compared to the consensus estimate of $64.22 million. Amphastar Pharmaceuticals had a negative net margin of 3.39% and a positive return on equity of 2.15%. Amphastar Pharmaceuticals’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.11 EPS. research analysts forecast that Amphastar Pharmaceuticals will post 0.1 earnings per share for the current year.

AMPH has been the topic of several recent analyst reports. ValuEngine raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Zacks Investment Research cut Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 15th. Finally, BidaskClub raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $21.00.

In other Amphastar Pharmaceuticals news, insider Jason B. Shandell sold 14,399 shares of the company’s stock in a transaction on Wednesday, July 11th. The stock was sold at an average price of $16.77, for a total value of $241,471.23. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO William J. Peters sold 2,407 shares of the company’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $17.59, for a total value of $42,339.13. Following the completion of the transaction, the chief financial officer now directly owns 86,836 shares in the company, valued at approximately $1,527,445.24. The disclosure for this sale can be found here. Insiders sold 45,056 shares of company stock worth $763,305 in the last ninety days. 31.50% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Featured Article: Dividend Stocks – Are They Right For You?

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with's FREE daily email newsletter.